Validation of proteins such as CAIX or GLUT1 as intrinsic markers of cellular hypoxia is clearly important to facilitate the routine study of tumour hypoxia in clinical trials and ultimately to use this to direct clinical practice outside trials. This evidence concerns the gene CA9 and neoplasm.